Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Joseph J. Maly has a total of 25 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • A Phase I/II Trial of Panobinostat in Combination With Lenalidomide in Patients With Relapsed or Refractory Hodgkin Lymphoma

    by Joseph J. Maly, Beth A. Christian, Xiaohua Zhu, Lai Wei, Jennifer L. Sexton, Samantha M. Jaglowski, Steven M. Devine, Todd A. Fehniger, Nina D. Wagner-Johnston, Mitch A. Phelps, et al.


  • Association of complex karyotype with inferior progression-free and overall survival in mantle cell lymphoma.

    by I Brian Greenwell, Ashley Darnell Staton, Michael J Lee, Jeffrey M. Switchenko, Joseph J. Maly, Kristie A. Blum, Natalie Sophia Grover, Stephanie Mathews, Steven I. Park, Max J Gordon, et al.

    7565 Background: Complex karyotype (CK) has been associated with inferior outcomes in mantle cell lymphoma (MCL) and other hematologic malignancies, including, but has only been evaluated in small MCL cohorts. We conducted a multi-center assessment of the impact of a CK on progression-free (PFS) and overall survival (OS) in patients with previously untreated MCL. Methods: Untreated patients (pts) with MCL from 4 academic centers diagnosed between 1993 and 2015 were included. Pts with 3 or more chromosomal abnormalities were defined as having CK. We described differences in clinical variables of interest between pts with and without CK and used the Kaplan-Meier method to estimate OS and PFS for each group. Multiple variable (MV) Cox regression analyses including MIPI components and demographics were performed to identify independent predictors of PFS and OS. Results: Of 248 pts, 89% had stage IV disease, and 19% had a CK (n = 48). The most common induction regimens included: R-HCVAD(n = 45), BR(n = 28), methotrexate with augmented R-CHOP(n = 36), and R-CHOP (n = 36). Median PFS was 2.2 years for pts with CK, and 4.5 years for pts without CK. Median OS was 4.5 years with CK, and 11.6 years without CK. Among 94 (37%) patients undergoing autologous stem cell transplant (ASCT) in 1st remission, the median PFS was 3.6 years for CK and 6.7 years without CK (p < 0.001) while the median OS was 5.1 years for CK and 8.6 years without CK (p = 0.023). Among pts who did not undergo ASCT in first remission (n = 107), the median PFS was 1.4 years for CK and 3.8 years for without CK (p = 0.002) and the median OS was 3.2 years for CK and not reached for without CK (p < 0.001). In MV analysis, CK (hazard ratio [HR] = 2.51) and ASCT in 1st remission (HR = 0.44) were the only predictors of PFS, and CK (HR = 2.36) was the only independent predictor for OS. Conclusions: CK is independently associated with inferior OS and PFS, regardless of the receipt of ASCT. Future studies should prospectively evaluate CK to aid in identifying high-risk patients for alternative therapies which may improve long-term outcomes.


  • Deferred treatment as a viable option for selected patients with mantle cell lymphoma.

    by Oscar Calzada, Jeffrey M. Switchenko, Joseph J. Maly, Kristie A. Blum, Natalie Sophia Grover, Stephanie Mathews, Steven I. Park, Max J Gordon, Alexey Valeryevich Danilov, Christopher Flowers, et al.

    7567 Background: While mantle cell lymphoma (MCL) has historically been treated at the time of diagnosis, we recently reported a national cohort analysis which identified a subset of patients who can safely defer therapy (Cohen et. al, ASH 2015), validating previously reported single-center findings (Martin et al, JCO 2009). We conducted a multicenter analysis of MCL patients with additional clinical data to better describe the role of deferred therapy in MCL. Methods: Patients ≥ 18 years old who received initial treatment for newly diagnosed MCL between 1995-2015 at one of four academic sites were included. Deferred therapy was defined as receipt of first treatment > 90 days following diagnosis. We identified variables associated with receipt of deferred therapy and evaluated the impact of deferred therapy, demographic factors and MIPI components on progression-free (PFS) and overall survival (OS) in multivariable regression models. Results: Of 356 patients, 71 (20%) received deferred therapy with a median time to treatment for this group of 234 days. Among all patients, the median age at diagnosis was 62 years, 72% were male, 95% were stage III/IV, and 32% presented with B symptoms. Patients receiving deferred therapy were more likely to have an ECOG performance status of 0 (68% vs 49% p = 0.009), lack B symptoms (83% vs 65% p = 0.004) and have normal LDH levels at diagnosis (87% vs 57% p < 0.001). Patients receiving immediate treatment more commonly had bone marrow involvement (84% vs 71% p = 0.016) and splenomegaly (58% vs 41% p = 0.015). In multivariable analysis presence of complex karyotype (CK; ≥ 3 chromosomal abnormalities) was the only significant predictor of inferior OS (HR 3.17, 95% CI 1.69-5.95). Deferred therapy was not associated with differences in OS (HR 0.64: 95% CI 0.30-1.33, p = 0.228), and there was no significant difference in frequency of a CK between the deferred and immediate therapy groups (p = 0.3). Conclusions: This retrospective, multi-center cohort analysis validates prior findings that deferred therapy may be a safe option for a subgroup of MCL patients. Future studies are needed to better identify suitable candidates for deferred therapy.


  • Open Access

    Pertuzumab in Combination with Trastuzumab and Chemotherapy in the Treatment of HER2-Positive Metastatic Breast Cancer: Safety, Efficacy, and Progression Free Survival

    by Joseph J. Maly, Erin R. Macrae

    Tyrosine kinase inhibitors have revolutionized the oncology community and were pioneered by the use in HER2-targeted therapies. Improved outcomes were seen with the advent of trastuzumab, leading investigators to develop newer agents to target the HER2 pathway such as the novel monoclonal antibody pertuzumab. In this paper, we describe the attributes of pertuzumab including: mechanism of action, pharmacokinetics and metabolism, safety/cardiotoxicity, drug interactions, efficacy, and role in HER2-positive breast cancer management. Newly reviewed here versus previously published reviews on pertuzumab oriented therapy are data of pertuzumab monotherapy as it is used in combination with other anti-HER2 agents derived from preclinical research and ongoing clinical trials. Materials and Methods: A computer based literature search was carried out using PubMed data reported at international meetings (ASCO) up to September 2013 were included.